The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:1175-1176 March 15, 2007 Number 11
NextNext

PET Scanning in Mild Cognitive Impairment

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Small, G. W.
-PubMed Citation
To the Editor: The report by Small and colleagues (Dec. 21 issue)1 on the use of positron-emission tomography (PET) after injection of 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl} ethylidene) malononitrile (FDDNP) to estimate the risk of Alzheimer's disease in persons with mild cognitive impairment raises the question of the clinical criteria for the diagnosis of this disease. The current criteria of the National Institute of Neurological Disorders and Stroke–Alzheimer's Disease and Related Disorder Association for diagnosing Alzheimer's disease clinically are 20 years old. If FDDNP-PET is validated, it will pose several questions.

First, will the terms "probable" and "possible" Alzheimer's disease become outdated? Will there . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.